These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 23285693)
1. Valproic acid enhances cisplatin cytotoxicity in melanoma cells. Chodurek E; Orchel A; Gruchlik A; Aleksander E; Gołabek K; Dzierzewicz Z Acta Pol Pharm; 2012; 69(6):1298-302. PubMed ID: 23285693 [TBL] [Abstract][Full Text] [Related]
2. Effect of valproic acid on the proliferation and apoptosis of the human melanoma G-361 cell line. Chodurek E; Kulczycka A; Orchel A; Aleksander-Konert E; Dzierzewicz Z Acta Pol Pharm; 2014; 71(6):917-21. PubMed ID: 25745763 [TBL] [Abstract][Full Text] [Related]
3. Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells. Papi A; Ferreri AM; Rocchi P; Guerra F; Orlandi M Anticancer Res; 2010 Feb; 30(2):535-40. PubMed ID: 20332466 [TBL] [Abstract][Full Text] [Related]
4. Examination by EPR spectroscopy of free radicals in melanins isolated from A-375 cells exposed on valproic acid and cisplatin. Chodurek E; Zdybel M; Pilawa B; Dzierzewicz Z Acta Pol Pharm; 2012; 69(6):1334-41. PubMed ID: 23285699 [TBL] [Abstract][Full Text] [Related]
5. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro. Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363 [TBL] [Abstract][Full Text] [Related]
6. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485 [TBL] [Abstract][Full Text] [Related]
7. Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity. Tesei A; Brigliadori G; Carloni S; Fabbri F; Ulivi P; Arienti C; Sparatore A; Del Soldato P; Pasini A; Amadori D; Silvestrini R; Zoli W J Cell Physiol; 2012 Oct; 227(10):3389-96. PubMed ID: 22212895 [TBL] [Abstract][Full Text] [Related]
8. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells. Groh T; Hrabeta J; Poljakova J; Eckschlager T; Stiborova M Neuro Endocrinol Lett; 2012; 33 Suppl 3():16-24. PubMed ID: 23353839 [TBL] [Abstract][Full Text] [Related]
9. Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Valentini A; Gravina P; Federici G; Bernardini S Cancer Biol Ther; 2007 Feb; 6(2):185-91. PubMed ID: 17218782 [TBL] [Abstract][Full Text] [Related]
10. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Facchetti F; Previdi S; Ballarini M; Minucci S; Perego P; La Porta CA Apoptosis; 2004 Sep; 9(5):573-82. PubMed ID: 15314285 [TBL] [Abstract][Full Text] [Related]
11. Valproic acid (VPA) enhances cisplatin sensitivity of non-small cell lung cancer cells via HDAC2 mediated down regulation of ABCA1. Chen JH; Zheng YL; Xu CQ; Gu LZ; Ding ZL; Qin L; Wang Y; Fu R; Wan YF; Hu CP Biol Chem; 2017 Jun; 398(7):785-792. PubMed ID: 28002023 [TBL] [Abstract][Full Text] [Related]
12. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388 [TBL] [Abstract][Full Text] [Related]
13. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692 [TBL] [Abstract][Full Text] [Related]
15. Additive Interaction of Cisplatin and Histone Deacetylase Inhibitors Combined Treatment in Rhabdomyosarcoma Cells - An Isobolographic Analysis. Jarząb A; Łuszczki JJ; Guz M; Gumbarewicz E; Polberg K; Stepulak A Anticancer Res; 2017 Mar; 37(3):1067-1074. PubMed ID: 28314266 [TBL] [Abstract][Full Text] [Related]
16. Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death. Yamanegi K; Yamane J; Kobayashi K; Kato-Kogoe N; Ohyama H; Nakasho K; Yamada N; Hata M; Fukunaga S; Futani H; Okamura H; Terada N Int J Oncol; 2012 Jul; 41(1):83-91. PubMed ID: 22576685 [TBL] [Abstract][Full Text] [Related]
17. Azidothymidine inhibits melanoma cell growth in vitro and in vivo. Humer J; Ferko B; Waltenberger A; Rapberger R; Pehamberger H; Muster T Melanoma Res; 2008 Oct; 18(5):314-21. PubMed ID: 18781129 [TBL] [Abstract][Full Text] [Related]
18. Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells. Iwata S; Saito T; Ito Y; Kamakura M; Gotoh K; Kawada J; Nishiyama Y; Kimura H Cancer Sci; 2012 Feb; 103(2):375-81. PubMed ID: 22017376 [TBL] [Abstract][Full Text] [Related]
19. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Greenblatt DY; Vaccaro AM; Jaskula-Sztul R; Ning L; Haymart M; Kunnimalaiyaan M; Chen H Oncologist; 2007 Aug; 12(8):942-51. PubMed ID: 17766653 [TBL] [Abstract][Full Text] [Related]
20. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Blaheta RA; Michaelis M; Driever PH; Cinatl J Med Res Rev; 2005 Jul; 25(4):383-97. PubMed ID: 15637697 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]